Photobiomodulation Therapy Reduces Neuropathic Pain, Improves Nerve Function in Diabetic and Cancer Patients
Background
Diabetic peripheral neuropathy (DPN) and chemotherapy-induced peripheral neuropathy (CIPN) are prevalent, debilitating complications significantly impairing quality of life and daily function. Current treatments often focus on symptomatic relief, failing to address the underlying neurovascular-immune pathology or promote nerve regeneration directly. This gap necessitates exploring non-pharmacological, non-invasive strategies. Photobiomodulation therapy (PBMT), utilizing specific light wavelengths, is being investigated for its potential to modulate cellular processes, offering a novel approach to nerve repair and pain management in these challenging conditions.
Study Design
This narrative review systematically evaluated the therapeutic potential of photobiomodulation therapy (PBMT) for peripheral neuropathy, specifically focusing on DPN and CIPN. Researchers conducted a comprehensive literature search across PubMed, Scopus, and Google Scholar databases for studies published between 2010 and 2025. The inclusion criteria focused on English-language studies investigating PBMT's effects on peripheral neuropathy, neuropathic pain, nerve regeneration, relevant biomarkers, and quality of life outcomes. The methodology aimed to synthesize existing evidence on PBMT's efficacy and safety in these patient populations.
Results
Current evidence suggests that photobiomodulation therapy (PBMT) offers multiple beneficial effects in managing peripheral neuropathy. The review highlighted PBMT's capacity to significantly reduce neuropathic pain, improve nerve conduction velocity, and enhance sensory function in patients afflicted with DPN and CIPN. Furthermore, PBMT was found to improve overall quality of life in these patient groups. Mechanistically, PBMT demonstrated positive impacts on neurobiological biomarkers, including a reduction in calcitonin gene-related peptide (CGRP) and an increase in neuron-specific enolase (NSE), indicating neuroprotective and regenerative effects. Its anti-inflammatory properties and ability to regulate mitochondrial function are believed to contribute to nerve regeneration and tissue repair. These findings collectively support PBMT as a promising intervention.
PBMT consistently improved nerve conduction, enhanced sensory function, and reduced neuropathic pain across various studies in DPN and CIPN patients, alongside positive biomarker modulation.
Key Findings
- PBMT reduces neuropathic pain in patients with DPN and CIPN.
- PBMT improves nerve conduction and enhances sensory function.
- PBMT improves quality of life for individuals with DPN and CIPN.
- PBMT positively influences neurobiological biomarkers like
calcitonin gene-related peptideandneuron-specific enolase. - PBMT exhibits anti-inflammatory and mitochondrial regulatory effects, contributing to nerve regeneration.
Why It Matters
This review underscores that photobiomodulation therapy (PBMT) represents a promising, non-invasive therapeutic strategy for managing peripheral neuropathy in diabetic and cancer patients, offering a significant potential improvement over current symptomatic treatments. For individuals struggling with chronic neuropathic pain and functional deficits, PBMT could provide a safe, accessible option to enhance quality of life and potentially promote nerve repair. While the evidence supports its safety and efficacy, the immediate clinical translation requires further steps. Large-scale randomized clinical trials are critically needed to standardize treatment protocols, including optimal wavelength, dose, frequency, and duration, to establish clear, usable guidelines for clinicians and biohackers. This could lead to PBMT being integrated as a complementary or primary therapy, particularly for those unresponsive to conventional approaches.
photobiomodulation
peripheral-neuropathy
diabetic-neuropathy
chemotherapy-induced-neuropathy
pain-management
nerve-regeneration